Performance of contrast-enhanced sonography vs MRI with a liver-specific contrast agent for diagnosis of hepatocellular adenoma and focal nodular hyperplasia
American Journal of Roentgenology Oct 11, 2019
Bröker MEE, Taimr P, de Vries M, et al. - Whether contrast-enhanced sonography (CEUS) with sulfur hexafluoride or MRI with the liver-specific contrast agent gadobenate dimeglumine affords a better tool to diagnose hepatocellular adenoma (HCA) and focal nodular hyperplasia (FNH), was investigated in this study performed on a cohort of consecutive patients. A prospective workup that involved CEUS and MRI with a liver-specific contrast agent was performed in patients who were referred to a tertiary center for hepatobiliary disease and had suspected HCA or FNH on MRI performed with an extracellular gadolinium-based contrast agent. In relation to concordant findings from CEUS and MRI with a liver-specific contrast agent, a definite diagnosis was made; cases with discordant findings were analyzed via histopathologic examination (HPE). For the diagnosis of HCA and FNH, a fair agreement was shown by the findings of CEUS and MRI with a liver-specific contrast agent. The diagnostic accuracy of MRI with a liver-specific contrast agent was significantly more common as compared with CEUS in cases with discordant findings that were HPE proven.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries